Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Br J Clin Pharmacol ; 90(8): 2030-2033, 2024 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-38803188

RESUMO

We present a 70-year-old female patient diagnosed with epidermal growth factor receptor-mutated metastatic non-small cell lung cancer (T4N2M1a), who developed afatinib-induced toxic epidermal necrolysis (TEN). We have also performed a PubMed/Medline literature review to detect other possible cases of TEN/Stevens-Johnson syndrome associated with afatinib treatment and found only 5 other cases reported. To our best knowledge, this is the first case of afatinib-induced TEN successfully treated with cyclosporine.


Assuntos
Afatinib , Carcinoma Pulmonar de Células não Pequenas , Neoplasias Pulmonares , Síndrome de Stevens-Johnson , Humanos , Afatinib/efeitos adversos , Afatinib/uso terapêutico , Feminino , Idoso , Síndrome de Stevens-Johnson/etiologia , Síndrome de Stevens-Johnson/tratamento farmacológico , Neoplasias Pulmonares/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Quinazolinas/efeitos adversos , Quinazolinas/uso terapêutico , Antineoplásicos/efeitos adversos , Ciclosporina/efeitos adversos , Ciclosporina/uso terapêutico , Receptores ErbB/antagonistas & inibidores , Receptores ErbB/genética
2.
Cancers (Basel) ; 15(11)2023 Jun 04.
Artigo em Inglês | MEDLINE | ID: mdl-37297014

RESUMO

Immunotherapy has improved the prognosis of metastatic melanoma patients, although most patients do not achieve a complete response. While specific gut microbiome and dietary habits might influence treatment success, there is a lack of concordance between the studies, potentially due to dichotomizing patients only into responders and non-responders. The aim of this study was to elucidate whether metastatic melanoma patients with complete and sustained response to immunotherapy exhibit differences in gut microbiome composition among themselves, and whether those differences were associated with specific dietary habits. Shotgun metagenomic sequencing revealed that patients who exhibited a complete response after more than 9 months of treatment (late responders) exhibited a significantly higher beta-diversity (p = 0.02), with a higher abundance of Coprococcus comes (LDA 3.548, p = 0.010), Bifidobacterium pseudocatenulatum (LDA 3.392, p = 0.024), and lower abundance of Prevotellaceae (p = 0.04) compared to early responders. Furthermore, late responders exhibited a different diet profile, with a significantly lower intake of proteins and sweets and a higher intake of flavones (p < 0.05). The research showed that metastatic melanoma patients with a complete and sustained response to immunotherapy were a heterogeneous group. Patients with a late complete response exhibited microbiome and dietary habits which were previously associated with an improved response to immunotherapy.

3.
Expert Rev Pharmacoecon Outcomes Res ; 16(5): 609-618, 2016 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26671843

RESUMO

The prescribing of medicines is a fundamental component of care for the elderly; however, there is increasing concern with polypharmacy and its impact on morbidity, mortality and costs. As a result, long-term prescription-medicine use and the prevalence of polypharmacy in the elderly in the Republic of Srpska were analyzed. The findings were subsequently used to suggest potential future measures. A retrospective study of all elderly patients during 2005-2010 stratified by age group (three groups), sex and long-term medicine use was performed. Polypharmacy (five or more medicines) increased from 1.4% of the elderly taking medicines long-term to 3.6% by 2010, with 53.6% of elderly taking two or more medicines long-term. The most prevalent diseases were cardiovascular diseases and diabetes. Most prescriptions were in accordance with recent guidelines; however, there was a concern with appreciable prescribing of digoxin and aminophylline. Whilst polypharmacy rates are low in the Republic, the increasing rate is a concern. Further studies are planned.


Assuntos
Polimedicação , Padrões de Prática Médica/normas , Medicamentos sob Prescrição/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Bósnia e Herzegóvina , Doenças Cardiovasculares/tratamento farmacológico , Doenças Cardiovasculares/epidemiologia , Diabetes Mellitus/tratamento farmacológico , Diabetes Mellitus/epidemiologia , Feminino , Humanos , Masculino , Guias de Prática Clínica como Assunto , Prevalência , Estudos Retrospectivos , Fatores de Tempo
4.
Expert Rev Clin Pharmacol ; 8(1): 77-94, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25487078

RESUMO

Medicines have made an appreciable contribution to improving health. However, even high-income countries are struggling to fund new premium-priced medicines. This will grow necessitating the development of new models to optimize their use. The objective is to review case histories among health authorities to improve the utilization and expenditure on new medicines. Subsequently, use these to develop exemplar models and outline their implications. A number of issues and challenges were identified from the case histories. These included the low number of new medicines seen as innovative alongside increasing requested prices for their reimbursement, especially for oncology, orphan diseases, diabetes and HCV. Proposed models center on the three pillars of pre-, peri- and post-launch including critical drug evaluation, as well as multi-criteria models for valuing medicines for orphan diseases alongside potentially capping pharmaceutical expenditure. In conclusion, the proposed models involving all key stakeholder groups are critical for the sustainability of healthcare systems or enhancing universal access. The models should help stimulate debate as well as restore trust between key stakeholder groups.


Assuntos
Atenção à Saúde/métodos , Descoberta de Drogas/métodos , Revisão de Uso de Medicamentos/métodos , Preparações Farmacêuticas/administração & dosagem , Ensaios Clínicos Fase III como Assunto , Indústria Farmacêutica/métodos , Humanos
5.
Pharmacoepidemiol Drug Saf ; 17(7): 733-7, 2008 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-18050360

RESUMO

PURPOSE: The objective of this study was to evaluate the prevalence of potential drug-drug interactions (DDIs) in hospitalised patients in correlation with patient's age and number of drugs prescribed and to determine the prevalence of inappropriate drugs prescribed to elderly patients. METHODS: Drugs prescribed during 1 day to all hospitalised patients at seven wards of Department of Medicine in University Hospital Rijeka were recorded by reviewing patient medical charts. Potential DDIs were evaluated using a list of potentially harmful drug combinations compiled from the literature. Beers criteria were used to identify potentially inappropriate medications in patients aged 65 years or older. RESULTS: The study included 225 patients that received a total of 1301 drugs. Twenty-two percent of the patients receiving drug therapy were prescribed drug combinations that are potentially harmful. The most common potentially harmful drug combination was an ACE inhibitor with a potassium supplement (33.9% of all combinations). In the multivariate analysis, age and number of drugs are significantly associated with potential DDIs (r = 0.8629). One quarter of elderly patients received a drug potentially inappropriate considering their age. The most commonly prescribed potentially inappropriate drug was amiodarone, followed by diazepam. CONCLUSION: Polypharmacy and older age have been proven to be important risk factors for potential drug interactions. We identified a high rate of prescribing potentially inappropriate medications among elders. Results of this study indicate that particular caution should be given when prescribing drugs to patients already receiving drugs and to elderly patients, considering the risk of drug-related problems.


Assuntos
Erros de Medicação/estatística & dados numéricos , Polimedicação , Padrões de Prática Médica/normas , Fatores Etários , Idoso , Amiodarona/efeitos adversos , Inibidores da Enzima Conversora de Angiotensina/efeitos adversos , Croácia , Diazepam/efeitos adversos , Interações Medicamentosas , Hospitalização , Hospitais Universitários , Humanos , Análise Multivariada , Compostos de Potássio/efeitos adversos , Prevalência , Fatores de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA